Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $24

HC Wainwright & Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $18 to $24.
byBenzinga Newsdesk
December 21, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $18 to $24.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Expert Ratings For Beyond Meat

By Benzinga Insights
Today, 5:38 AM
Over the past 3 months, 4 analysts have published their opinion on Beyond Meat (NASDAQ:BYND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

BYND